Trends in recognition and treatment of dementia in france analysis of the 2004 to 2010 database of the national health insurance plan

Alzheimer Disease and Associated Disorders

Volumn 27, Issue 3, 2013, Pages 213-217

  Bertrand, Marion ^a,b,c   Tzourio, Christophe ^a,b,c   Alpérovitch, Annick ^a,b,c  

^a INSERM   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c UNIVERSITÉ DE BORDEAUX   (France)

Author keywords

Dementia recognition; pharmacoepidemiology; population study; temporal trends

Indexed keywords

CHOLINESTERASE INHIBITOR; MEMANTINE; NOOTROPIC AGENT;

AGED; ALZHEIMER DISEASE; ARTICLE; DEMENTIA; FEMALE; FRANCE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEALTH STATUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIINFARCT DEMENTIA; NATIONAL HEALTH INSURANCE; PHARMACOEPIDEMIOLOGY; POPULATION RESEARCH; PRIORITY JOURNAL; PUBLIC HEALTH SERVICE; QUALITY OF LIFE; REIMBURSEMENT; FACTUAL DATABASE; PUBLIC HEALTH; VERY ELDERLY;

AGED; AGED, 80 AND OVER; CHOLINESTERASE INHIBITORS; DATABASES, FACTUAL; DEMENTIA; FEMALE; FRANCE; HUMANS; MALE; NATIONAL HEALTH PROGRAMS;

EID: 84883285686     PISSN: 08930341     EISSN: None     Source Type: Journal    
DOI: 10.1097/WAD.0b013e3182695a3b     Document Type: Article

References (23)

1. Vidal JS, Lacombe JM, Dartigues JF, et al. Memantine therapy for Alzheimer disease in real-world practice-an observational study in a large representative sample of French patients. Alzheimer Dis Assoc Disord. 2008;22:125-130.
2. World Health Organization. International Classification of Diseases 10th Revision. Geneva: World Health Organization; 1993.
3. Massoud F, Léger GC. Pharmacological treatment of Alzheimer disease. Can J Psychiatry. 2001;56:579-588.
4. Dufouil C, Richard F, Fiévet N, et al. APOE genotype, cholesterol level, lipid-lowering treatment, and dementia-the Three-City Study. Neurology. 2005;64:1531-1538.
5. Katz MJ, Lipton RB, Hall CB, et al. Age-specific and sexspecific prevalence of mild cognitive impairment, dementia, and Alzheimer's disease in blacks and whites: a report from the Einstein Aging Study. Alzheimer Dis Assoc Disord. 2011. [Epub ahead of print].
6. Franchi C, Lucca U, Tettamanti M, et al. Cholinesterase inhibitor use in Alzheimer's disease: the EPIFARMElderly Project. Pharmacoepidemiol Drug Safety. 2011;20: 497-505.
7. Gruber-Baldini A, Stuart B, Zuckerman I, et al. Treatment of dementia among community-dwelling and institutionalized Medicare beneficiaries. J American Geriatrics Society. 2007; 55:1508-1516.
8. Hofman A, Rocca W, Brayne C, et al. The prevalence of dementia in Europe: a collaborative study of 1980-1990 findings. Int J Epidemiol. 1991;20:736-748.
9. Berr C, Akbaraly T, Nourashemi F, et al. Epidemiology of dementia. Presse Médicale. 2007;36:1431-1441.
10. Ramaroson H, Helmer C, Barberger-Gateau P, et al. Prevalence of dementia and Alzheimer's disease among subjects aged 75 years and over: updated results of the PAQUID cohort. Rev Neurol. 2003;159:405-411.
11. Rosenblatt A, Samus QM, Steele CD, et al. The Maryland Assisted Living Study: prevalence, recognition, and treatment of dementia and other psychiatric disorders in the assisted living population of central Maryland. J Am Geriatr Soc. 2004;52:1618-1625.
12. Maggini M, Salmaso S, Spila Legiani S, et al. Epidemiological use of drug prescription as markers of disease frequency: an Italian experience. J Clin Epidemiol. 1991;44:1299-1307.
13. Becher H, Kostev K, Schro? der-Bernardi D. Validity and representativeness of the ?Disease Analyzer? patient database for use in pharmacoepidemiological and pharmacoeconomic studies. Int J Clin Pharmacol Ther. 2009;47:617-626.
14. de Pedro Cuesta J, Petersen IJ, Vassilopoulos D, et al. Epidemiological assessment of levodopa use by populations. Acta Neurol Scand. 1991;85:328-335.
15. van de Vijver DAMC, Porsius AJ, BHCh Stricker, et al. Evaluation of antiparkinsonian drugs in pharmacy records as a marker of Parkinson's disease. Int J Clin Pharmacy. 2001;23:148-152.
16. Moisan F, Gourlet V, Mazurie JL, et al. Prediction model of Parkinson's disease based on antiparkinsonian drug claims. Am J Epidemiol. 2011;174:354-363.
17. Chien IC, Lin YC, Chou YJ, et al. Treated prevalence and incidence of dementia among national health insurance enrollees in Taiwan, 1996-2003. J Geriatr Psychiatr Neurol. 2008;21:142-148.
18. Tuppin P, Cuerq A, Weill A, et al. Alzheimer disease and other dementia in France: identification, management and neuroleptic use. Rev Neurol. 2012;168:152-160.
19. Vidal JS, Lacombe JM, Dartigues JF, et al. Memantine therapy for Alzheimer disease in real-world practice: an observational study in a large representative sample of French patients. Alzheimer Dis Assoc Disord. 2008;22:125-130.
20. Rait G, Walters K, Bottomley C, et al. Survival of people with clinical diagnosis of dementia in primary care: cohort study. BMJ. 2010;341:c3584.
21. Villarejo A, Benito-Leó n J, Trincado R, et al. Dementiaassociated mortality at thirteen years in the NEDICES cohort study. J Alzheimers Dis. 2011;26:543-551.
22. Helmer C, Joly P, Letenneur L, et al. Mortality with dementia: results from a French prospective community-based cohort. Am J Epidemiol. 2001;154:642-648.
23. Cohen CI, McKenzie SE, Rahmani M, et al. Historical changes in the severity of dementia and accompanying neuropsychiatric disorders symptoms in persons presenting for evaluation in a multiracial urban dementia center. Alzheimer Dis Assoc Disord. 2012. [Epub ahead of print].